Drug Profile
Rhodamine 123
Alternative Names: R 123Latest Information Update: 10 Sep 2003
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 09 Mar 2001 Phase-I clinical trials in Prostate cancer in USA (unspecified route)